TobraDex

The exact 3 mg/g + 1 mg/g 3.5 g human ointment has transparent NDA 050616 identity and current Georgian, EU/EEA and US human authorisations. The inherited GB row was a suspension mismatch and is corrected to unknown exact-form status. No veterinary authorisation exists, and exact-product target-species evidence is absent or limited to one confounded canine case; the evidence gate caps this axis at 4.0.

One exact-ointment canine MGD/blepharitis case improved during ointment plus systemic doxycycline, warm compresses, lid massage and dermatologic care; it cannot isolate efficacy or generalise across ocular disease. Exact rabbit PK confirms delivery but not canine benefit, and dexamethasone increased tobramycin resistance/MIC in canine S. pseudintermedius isolates.

Correct selection can reduce harm, but dexamethasone can delay epithelial healing, mask or enhance infection, raise IOP and contribute to perforation in thinned cornea; the ointment itself may retard healing. Repeated topical 0.1% dexamethasone produced systemic absorption and cortisol suppression in dogs. Exact repeated-ointment target-animal safety is absent.

The sterile ready tube needs no shaking and longer surface residence may suit selected lid/anterior-surface disease. Ribbon length is imprecise, ointment blurs vision and requires atraumatic restraint, tip hygiene and placement after other drops; examination, IOP decisions and early recheck remain substantial but appropriate clinical work.

The exact 3 mg/g + 1 mg/g 3.5 g human ointment has transparent NDA 050616 identity and current Georgian, EU/EEA and US human authorisations. The inherited GB row was a suspension mismatch and is corrected to unknown exact-form status. No veterinary authorisation exists, and exact-product target-species evidence is absent or limited to one confounded canine case; the evidence gate caps this axis at 4.0.

No exact-ointment feline outcome trial was found. Human-label activity, rabbit PK and one confounded canine case are indirect, while common feline herpesvirus disease can make the steroid inappropriate; pure-tobramycin susceptibility cannot prove benefit of this fixed combination.

Ulcer, delayed-healing, infection, IOP and perforation hazards apply, while latent feline herpesvirus adds a species-specific risk. Exact feline PK and repeated-use safety are absent; aminoglycoside hypersensitivity, contamination and non-susceptible overgrowth remain possible.

A ready tube and longer residence may reduce placements, but ribbon length is difficult to quantify in a small painful eye. Greasy residue, temporary blur, restraint, contamination control, other-drop sequencing and early reassessment limit practicality, especially when FHV or another differential may require changing one component.

The exact 0.3%/0.1% human suspension has transparent FDA NDA 050592 identity and current Georgian, EU/EEA, GB and US human authorisations. The old NDA 050616 mapping belonged to ointment and is corrected here; no veterinary authorisation applies and dog/cat use remains off-label.

Exact TobraDex is documented in canine cataract and lens-emergency protocols, supporting a real narrow veterinary role, but outcomes are inseparable from surgery and multiple concurrent drugs. No clean exact-product canine trial was found, and a 2026 study found dexamethasone increased tobramycin resistance/MIC in canine S. pseudintermedius isolates.

A diagnostic error can cause vision-threatening harm: dexamethasone delays epithelial healing, can enhance collagenase-associated melting, mask infection and raise IOP. Four-times-daily 0.1% ophthalmic dexamethasone produced systemic absorption and cortisol suppression in dogs; BAK exposure, aminoglycoside sensitivity and microbial overgrowth add risk.

The 5 ml dropper gives a direct ocular unit without weight calculation, but this suspension must be shaken before every dose and needs repeated administration, careful restraint, contamination control, examination, IOP decisions and early recheck. A fixed combination is less adaptable when only one component should be changed.

The exact 0.3%/0.1% human suspension has transparent FDA NDA 050592 identity and current Georgian, EU/EEA, GB and US human authorisations. The old NDA 050616 mapping belonged to ointment and is corrected here; no veterinary authorisation applies and dog/cat use remains off-label.

No exact-product feline clinical outcome trial was found. Human exact-ratio data and canine multi-treatment experience provide only an indirect bridge, while common feline inflammatory eye disease may be herpetic and therefore steroid-inappropriate; pure-tobramycin susceptibility cannot prove benefit of the fixed combination.

The serious ulcer, infection, healing and IOP hazards apply, and topical corticosteroids can reactivate latent feline herpesvirus with ulcerative keratitis or sequestrum. Exact-product feline safety and systemic-absorption data are absent, so an intact stain today does not remove the need for viral history, lesion assessment and early recheck.

The dropper is directly measurable, but shaking, repeated atraumatic feline restraint, contamination control, examination and early recheck are material burdens. The fixed combination is particularly inflexible when herpesvirus or another differential makes dexamethasone inappropriate while antibacterial treatment is still being reconsidered.